

Peter Nash

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3627080/peter-nash-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141
papers

11,547
citations

46
h-index

106
g-index

175
ext. papers

13,598
ext. citations

5.8
avg. IF

5.76
L-index

#	Paper	IF	Citations
141	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	27.4	1649
140	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
139	Psoriatic arthritis: epidemiology, clinical features, course, and outcome. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii14-7	2.4	619
138	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015 , 373, 1329-39	59.2	508
137	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71	9.5	485
136	Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 508-16	2.4	440
135	Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 559-70		402
134	Treatment recommendations for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1387-94	2.4	386
133	Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1033-41		334
132	Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1939-50		298
131	The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3077-87		270
130	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. <i>Lancet, The</i> , 2013 , 381, 918-29	4.0	266
129	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1253-1262	2.4	257
128	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2317-2327	4.0	246
127	Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 964-75		212
126	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 986-91	2.4	192
125	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156

124	Assessment of patients with psoriatic arthritis: a review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004 , 50, 24-35		151
123	Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. <i>Lancet, The</i> , 2006 , 368, 855-63	4.0	145
122	Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2854-64		144
121	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 1167-70	4.1	144
120	Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1460-9	2.4	130
119	Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. <i>Journal of Rheumatology</i> , 2010 , 37, 1488-501	4.1	126
118	Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. <i>Rheumatology</i> , 2013 , 52, 155-60	3.9	122
117	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 123-131	2.4	116
116	The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1377-80	2.4	113
115	Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. <i>Arthritis Research and Therapy</i> , 2011 , 13, R211	5.7	108
114	Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 913-23	2.4	108
113	Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 919-24	6.3	101
112	Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. <i>Archives of Internal Medicine</i> , 2000 , 160, 2917-22		97
111	APLAR rheumatoid arthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 685-713	2.3	93
110	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020 , 395, 1496-1505	4.0	83
109	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018 , 20, 47	5.7	69
108	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015 , 67, 1237-1245	4.7	67
107	N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R143	5.7	65

106	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 7	5.7	63
105	2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 357-375	2.3	60
104	Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3234-44	9.5	58
103	Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. <i>Arthritis Care and Research</i> , 2013 , 65, 718-28	4.7	55
102	Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii74-7	2.4	54
101	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355	9.5	51
100	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
99	Randomized Crossover Comparison of Injection Site Pain with 40mg/0.4 or 0.8mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2016 , 3, 257-270	4.4	48
98	Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. <i>Rheumatology</i> , 2009 , 48 Suppl 3, iii25-31	3.9	48
97	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1293-301	2.4	47
96	Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. <i>Dermatology</i> , 2006 , 212, 238-49	4.4	47
95	Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 690-698	2.4	46
94	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 867-75		45
93	Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1987-97	5.5	42
92	An ImmunoChip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. <i>Arthritis Research and Therapy</i> , 2014 , 16, 438	5.7	42
91	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 878-891	9.5	38
90	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2013 , 15, R193	5.7	37
89	Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S111-6	2.2	37

88	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020 , 6,	5.9	36
87	Treatment goals for moderate to severe psoriasis: an Australian consensus. <i>Australasian Journal of Dermatology</i> , 2013 , 54, 148-54	1.3	36
86	Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials. <i>Arthritis Care and Research</i> , 2019 , 71, 367-378	4.7	36
85	Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009 , 36, 2356-61	4.1	32
84	Seronegative spondyloarthropathies: to lump or split?. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii9-13	2.4	32
83	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 848-858	2.4	32
82	Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. <i>Rheumatology and Therapy</i> , 2018 , 5, 99-122	4.4	31
81	Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. <i>Journal of Rheumatology</i> , 2010 , 37, 1885-91	4.1	31
80	Registries in systemic sclerosis: a worldwide experience. <i>Rheumatology</i> , 2011 , 50, 60-8	3.9	31
79	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 553-580	4.4	29
78	Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis Care and Research</i> , 2013 , 65, 1732-42	4.7	29
77	Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. <i>Journal of Rheumatology</i> , 2010 , 37, 105-15	4.1	29
76	Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2016 , 68, 744-52	4.7	28
75	Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2018 , 5, 567-582	4.4	28
74	Updated guidelines for the management of axial disease in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2286-9	4.1	27
73	Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. <i>Journal of Rheumatology</i> , 2014 , 41, 629-39	4.1	27
72	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1360-3	2.4	27
71	Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 757-66	4.5	26

70	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1310-1319	2.4	26
69	Therapies for axial disease in psoriatic arthritis. A systematic review. <i>Journal of Rheumatology</i> , 2006 , 33, 1431-4	4.1	25
68	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1107-1123	2.1	24
67	Efficacy and Safety of Subcutaneous Secukinumab 150mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. <i>Rheumatology and Therapy</i> , 2019 , 6, 393-407	4.4	23
66	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. <i>Journal of Rheumatology</i> , 2018 , 45, 1085-1092	4.1	23
65	Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. <i>Rheumatology</i> , 2018 , 57, 2001-2011	3.9	22
64	The complexity of managing systemic sclerosis: screening and diagnosis. <i>Rheumatology</i> , 2009 , 48 Suppl 3, iii8-13	3.9	22
63	Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 272	5.7	20
62	Advances in rheumatoid arthritis. <i>Medical Journal of Australia</i> , 2017 , 206, 221-224	4	19
61	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018 , 20, 242	5.7	17
60	OMERACT 7 psoriatic arthritis workshop: synopsis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii115-6	2.4	16
59	The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. <i>International Journal of Rheumatic Diseases</i> , 2009 , 12, 192-206	2.3	15
58	Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study. <i>Advances in Therapy</i> , 2017 , 34, 1157-1172 ¹⁴	4.1	14
57	Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study. <i>International Journal of Rheumatic Diseases</i> , 2013 , 16, 652-61	2.3	13
56	LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS 2019 ,		13
55	Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	13
54	Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. <i>Drug Safety</i> , 2021 , 44, 515-530	5.1	13
53	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. <i>Journal of Rheumatology</i> , 2018 , 45, 177-187	4.1	13

52	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , 2020 , 6,	5.9	12
51	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 497-510	2.1	11
50	Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. <i>RMD Open</i> , 2019 , 5, e000742	5.9	11
49	Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. <i>RMD Open</i> , 2018 , 4, e000692	5.9	11
48	Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study. <i>Clinical Therapeutics</i> , 2010 , 32, 1329-42	3.5	10
47	Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e227-e235	14.2	10
46	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020 , 6,	5.9	10
45	Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, 239-247	1.1	9
44	Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. <i>RMD Open</i> , 2021 , 7,	5.9	9
43	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 709-718	5.3	8
42	Inhibition of interleukins 17A and 17F in psoriatic arthritis. <i>Lancet, The</i> , 2020 , 395, 395-396	4.0	8
41	Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. <i>Clinical Rheumatology</i> , 2018 , 37, 1617-1623	3.9	8
40	Remission in psoriatic arthritis-where are we now?. <i>Rheumatology</i> , 2018 , 57, 1321-1331	3.9	8
39	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. <i>Rheumatology and Therapy</i> , 2018 , 5, 383-401	4.4	8
38	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. <i>RMD Open</i> , 2017 , 3, e000465	5.9	7
37	Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. <i>Lupus Science and Medicine</i> , 2017 , 4, e000206	4.6	7
36	Choosing the right treatment for patients with psoriatic arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20962623	3.8	7
35	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e270-e283	14.2	7

34	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011 , 13, 114	5.7	6
33	Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2018 , 5, 216-223	1.7	6
32	Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S47-52	2.2	6
31	Alefacept plus methotrexate for psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 470-1		5
30	Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. <i>Lancet Rheumatology, The</i> , 2021 , 3, e28-e39	14.2	5
29	Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. <i>Arthritis Research and Therapy</i> , 2021 , 23, 41	5.7	5
28	Psoriatic arthritis: novel targets add to a therapeutic renaissance. <i>Lancet, The</i> , 2018 , 391, 2187-2189	4.0	5
27	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 566-574	2.2	5
26	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.. <i>Rheumatology and Therapy</i> , 2021 , 9, 521	4.4	5
25	Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2019 , 6, 113-121	1.7	4
24	Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 1021-1033	4.4	4
23	The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 129-136	2.2	4
22	256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2019 , 58,	3.9	3
21	Assessment and treatment of psoriatic spondylitis. <i>Current Rheumatology Reports</i> , 2009 , 11, 278-83	4.9	3
20	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
19	Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
18	FRI0457 SECUKINUMAB PROVIDES SIGNIFICANT AND SUSTAINED IMPROVEMENT IN NAIL PSORIASIS AND SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WITH NAIL PHENOTYPE: 52-WEEK RESULTS FROM THE PHASE III FUTURE 5 STUDY 2019 ,		3
17	Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPQSS). <i>Journal of Rheumatology</i> , 2011 , 38, 2118-27	4.1	2

16	Anti-tumor necrosis factor therapy: the Australian experience. <i>APLAR Journal of Rheumatology</i> , 2006 , 9, 119-123		2
15	Clinical use of Jak 1 inhibitors for rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, ii31-ii38	3.9	2
14	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). <i>Rheumatology and Therapy</i> , 2021 , 8, 199-217	4.4	2
13	257 Secukinumab demonstrates a consistent safety profile with up to 5 years of treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. <i>Rheumatology</i> , 2019 , 58,	3.9	1
12	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	1
11	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal</i>	3.8	1
10	The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 11	5.7	1
9	A comparison of Janus kinase inhibitor safety in rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 3-14	2.3	1
8	Reply. <i>Arthritis Care and Research</i> , 2016 , 68, 1053-4	4.7	1
7	A patient-centered knowledge translation tool for treat-to-target strategy in rheumatoid arthritis: Patient and rheumatologist perspectives. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 355-363	2.3	1
6	The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels. <i>ACR Open Rheumatology</i> , 2021 , 3, 699-706	3.5	1
5	Initiative for quality in psoriasis and psoriatic arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1431-3	4.1	1
4	Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. <i>Rheumatology and Therapy</i> , 2021 , 8, 1827-1844	4.4	0
3	Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	0
2	Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry.. <i>Rheumatology and Therapy</i> , 2022 , 9, 735	4.4	0
1	Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.. <i>Rheumatology and Therapy</i> , 2021 , 9, 411	4.4	0